Company / Free Cash Flow
Bristol Myers Squibb Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$12.8B
FY2025
5-year range
$7.4B / $15.2B
FY2021-FY2025
Trend
-7.9%
vs FY2024
Sector context
#3 of 194
Health Care
What the data says
Among 194 Health Care companies, Bristol Myers Squibb is in the top 2% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from $1.8B in FY2018 to $15.2B in FY2023.
Based on SEC 10-K filings.
$12.8B in FY2025 with a 5-year CAGR of -0.7%. Ranks 3rd among 194 companies in Health Care.
Declined from $15.2B to $12.8B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -1.2%
- 5-Year CAGR
- -0.7%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 194This company $12.8B Sector average $470.6M
▼
+2629.7% above sector average
Key checks
Key Insights
- 5-year CAGR of -0.7%, indicating a declining trend.
- In FY2025, free cash flow decreased 7.9% year-over-year.
- Ranks #3 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2023.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.8B | -7.9% |
| FY2024 | $13.9B | -8.5% |
| FY2023 | $15.2B | +14.5% |
| FY2022 | $13.3B | +80.3% |
| FY2021 | $7.4B | -44.6% |
| FY2020 | $13.3B | +215.1% |
| FY2019 | $4.2B | +129.0% |
| FY2018 | $1.8B | -56.3% |
| FY2017 | $4.2B | +60.9% |
| FY2016 | $2.6B | -12.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026